Ex Parte Roser - Page 5


                 Appeal No.  2006-1335                                                        Page 5                  
                 Application No.  09/888,734                                                                          
                 factor VIII demonstrates that trehalose is recognized by the art as being a                          
                 cryoprotectant suitable in a number of varied applications.”  In this regard, we                     
                 agree with Helgerson (Declaration, paragraph 3), that the examiner has                               
                 overstepped the evidence on this record.  While it is undisputed that Curtis                         
                 discloses a method for preparing a purified and stable activated Factor VIII, as                     
                 appellant points out - the evidence with regard to Livesey is not as persuasive as                   
                 the examiner makes it out.  According to appellant (Reply Brief, page 4), “Livesey                   
                 does not teach the reader that trehalose, on its own and without albumin, can be                     
                 used to stabilize Factor VIII.”  In this regard, we note the examiner’s reliance on                  
                 claim 17, and column 9, lines16-24 of Livesey to teach that the biological material                  
                 comprises Factor VIII.5  Answer, page 4.  Claim 17 depends directly from claim 1                     
                 – but claim 1 does not limit the “cyroprotectant” to be used.  In this regard, we                    
                 direct the examiner’s attention to Livesey’s claim 8, which depends ultimately                       
                 from claim 1 and further limits the cyroprotectant to “a vitrification solution                      
                 comprising a mixture of” various chemicals.  Thus, consistent with Livesey’s                         
                 specification, the cyroprotectants are contemplated to be used “alone or in                          
                 combination with other cyroprotectants or with additional components. . . ”                          
                 (Livesey, column 9, lines 33-34) including albumin (Livesey, column 9, lines 5-                      
                 15).                                                                                                 


                                                                                                                      
                 requirement in any of appellant’s claims.  Accordingly, we are not persuaded by this argument.       
                 5 Interestingly enough, the examiner does not address what is encompassed by the term                
                 “comprises” as it appears in claim 17 of Livesey, which opens the claim to the inclusion of other    
                 components including e.g., albumin.  In addition, we note that the only other disclosure of Factor   
                 VIII in Livesey appears at column 4, lines 57-64, wherein Livesey discloses that “[t]he present      
                 invention can be used to preserve many different types of biological materials.  It is anticipated   
                 that the method can be used to preserve materials such as . . . Factor VIII . . . .”                 





Page:  Previous  1  2  3  4  5  6  7  8  9  Next 

Last modified: November 3, 2007